Mirikizumab

• CAT Number: I042088
• CAS Number: 1884201-71-1
• Purity: ≥95%

Mirikizumab（Cat No.:I042088）is an investigational monoclonal antibody targeting interleukin-23 (IL-23), a cytokine involved in the inflammatory process of several autoimmune diseases. By inhibiting IL-23, mirikizumab aims to reduce inflammation and modulate immune responses in conditions such as ulcerative colitis, Crohn’s disease, and psoriasis. It works by specifically blocking the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor, and thereby reducing the production of pro-inflammatory cytokines. Clinical trials are ongoing to assess its safety, efficacy, and potential as a therapeutic option for these chronic inflammatory diseases.